CR20190417A - Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas - Google Patents
Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadasInfo
- Publication number
- CR20190417A CR20190417A CR20190417A CR20190417A CR20190417A CR 20190417 A CR20190417 A CR 20190417A CR 20190417 A CR20190417 A CR 20190417A CR 20190417 A CR20190417 A CR 20190417A CR 20190417 A CR20190417 A CR 20190417A
- Authority
- CR
- Costa Rica
- Prior art keywords
- par2
- antibodies
- antigen
- binding fragments
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno capaces de unirse a PAR2. En algunas realizaciones, los anticuerpos anti-PAR2 o fragmentos de unión a antígeno de los mismos se unen a PAR2 de una manera dependiente del pH. La divulgación proporciona además métodos para preparar y usar los anticuerpos y fragmentos de unión a antígeno.The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472462P | 2017-03-16 | 2017-03-16 | |
| US201862637766P | 2018-03-02 | 2018-03-02 | |
| PCT/EP2018/056776 WO2018167322A1 (en) | 2017-03-16 | 2018-03-16 | Anti-par2 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190417A true CR20190417A (es) | 2019-12-06 |
Family
ID=61827709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190417A CR20190417A (es) | 2017-03-16 | 2018-03-16 | Anticuerpos anti-par2 y usos de los mismos referencia cruzada a solicitudes relacionadas |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US10836822B2 (es) |
| EP (2) | EP3596125B1 (es) |
| JP (3) | JP7222901B2 (es) |
| KR (1) | KR102711884B1 (es) |
| CN (1) | CN110446720B (es) |
| AU (3) | AU2018235031B2 (es) |
| BR (1) | BR112019018752A2 (es) |
| CA (1) | CA3055251A1 (es) |
| CL (1) | CL2019002626A1 (es) |
| CO (1) | CO2019010975A2 (es) |
| CR (1) | CR20190417A (es) |
| DK (1) | DK3596125T3 (es) |
| ES (1) | ES3056721T3 (es) |
| FI (1) | FI3596125T3 (es) |
| HR (1) | HRP20251643T1 (es) |
| IL (1) | IL269134B2 (es) |
| LT (1) | LT3596125T (es) |
| MA (1) | MA49886A (es) |
| MX (1) | MX2019010802A (es) |
| NZ (1) | NZ757915A (es) |
| PH (1) | PH12019502087A1 (es) |
| PL (1) | PL3596125T3 (es) |
| PT (1) | PT3596125T (es) |
| RS (1) | RS67581B1 (es) |
| SG (1) | SG11201908056QA (es) |
| SI (1) | SI3596125T1 (es) |
| TW (1) | TWI788332B (es) |
| UA (1) | UA125757C2 (es) |
| WO (1) | WO2018167322A1 (es) |
| ZA (1) | ZA201906004B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| CA2827923C (en) | 2011-02-25 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc antibody |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| SG10201710322VA (en) | 2014-12-19 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| BR112019001902A2 (pt) | 2016-08-05 | 2019-07-09 | Chugai Seiyaku Kabushiki Kaisha | composição para profilaxia ou tratamento de doenças relacionadas à il-8 |
| JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
| JP7222901B2 (ja) * | 2017-03-16 | 2023-02-15 | メドイミューン・リミテッド | 抗ｐａｒ２抗体及びその使用 |
| US12214216B1 (en) | 2019-10-16 | 2025-02-04 | Helen Feng | Photon enhanced bone growth system and method |
| HUE070287T2 (hu) | 2020-08-18 | 2025-05-28 | Cephalon Llc | Anti-PAR-2 ellenanyagok és eljárások alkalmazásukra |
| GB202204159D0 (en) | 2022-03-24 | 2022-05-11 | Heptares Therapeutics Ltd | Antibodies |
| AU2024212070A1 (en) | 2023-01-25 | 2025-07-31 | Medimmune Limited | Migraine therapy |
| WO2025172573A1 (en) | 2024-02-16 | 2025-08-21 | Domain Therapeutics | Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer |
| WO2025191185A1 (en) | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| EP1604207A2 (en) * | 2003-03-11 | 2005-12-14 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2) |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| AU2005304963C1 (en) * | 2004-11-04 | 2011-01-06 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
| US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
| CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
| AR070911A1 (es) | 2008-03-19 | 2010-05-12 | Regeneron Pharma | Uso de antagonistas del receptor par2 activado con proteasa |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| JP2011519279A (ja) | 2008-05-01 | 2011-07-07 | アムジエン・インコーポレーテツド | 抗ヘプシジン抗体及び使用の方法 |
| CA2733041A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Effectors of par-2 activation and their use in the modulation of inflammation |
| US8481690B2 (en) * | 2008-08-07 | 2013-07-09 | Idexx Laboratories, Inc. | Methods for detecting symmetrical dimethylarginine |
| JO3246B1 (ar) * | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| BR112012022917A2 (pt) | 2010-03-11 | 2017-01-10 | Pfizer | anticorpos com ligação a antígeno dependente de ph |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| EP2882778B1 (en) * | 2012-08-13 | 2018-04-11 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| ES2926376T3 (es) * | 2014-06-30 | 2022-10-25 | Merck Patent Gmbh | Anticuerpos anti-TNFa con unión al antígeno dependiente del pH |
| JP7222901B2 (ja) * | 2017-03-16 | 2023-02-15 | メドイミューン・リミテッド | 抗ｐａｒ２抗体及びその使用 |
-
2018
- 2018-03-16 JP JP2019549512A patent/JP7222901B2/ja active Active
- 2018-03-16 CR CR20190417A patent/CR20190417A/es unknown
- 2018-03-16 CN CN201880018128.7A patent/CN110446720B/zh active Active
- 2018-03-16 EP EP18714185.8A patent/EP3596125B1/en active Active
- 2018-03-16 HR HRP20251643TT patent/HRP20251643T1/hr unknown
- 2018-03-16 US US15/923,374 patent/US10836822B2/en active Active
- 2018-03-16 BR BR112019018752-9A patent/BR112019018752A2/pt unknown
- 2018-03-16 UA UAA201910275A patent/UA125757C2/uk unknown
- 2018-03-16 CA CA3055251A patent/CA3055251A1/en active Pending
- 2018-03-16 NZ NZ757915A patent/NZ757915A/en unknown
- 2018-03-16 MA MA049886A patent/MA49886A/fr unknown
- 2018-03-16 LT LTEPPCT/EP2018/056776T patent/LT3596125T/lt unknown
- 2018-03-16 SG SG11201908056QA patent/SG11201908056QA/en unknown
- 2018-03-16 AU AU2018235031A patent/AU2018235031B2/en active Active
- 2018-03-16 DK DK18714185.8T patent/DK3596125T3/da active
- 2018-03-16 MX MX2019010802A patent/MX2019010802A/es unknown
- 2018-03-16 PL PL18714185.8T patent/PL3596125T3/pl unknown
- 2018-03-16 ES ES18714185T patent/ES3056721T3/es active Active
- 2018-03-16 KR KR1020197030092A patent/KR102711884B1/ko active Active
- 2018-03-16 PT PT187141858T patent/PT3596125T/pt unknown
- 2018-03-16 FI FIEP18714185.8T patent/FI3596125T3/fi active
- 2018-03-16 WO PCT/EP2018/056776 patent/WO2018167322A1/en not_active Ceased
- 2018-03-16 EP EP25204633.9A patent/EP4681726A3/en active Pending
- 2018-03-16 TW TW107109179A patent/TWI788332B/zh active
- 2018-03-16 SI SI201831278T patent/SI3596125T1/sl unknown
- 2018-03-16 IL IL269134A patent/IL269134B2/en unknown
- 2018-03-16 RS RS20251336A patent/RS67581B1/sr unknown
-
2019
- 2019-09-11 ZA ZA2019/06004A patent/ZA201906004B/en unknown
- 2019-09-13 PH PH12019502087A patent/PH12019502087A1/en unknown
- 2019-09-13 CL CL2019002626A patent/CL2019002626A1/es unknown
- 2019-10-03 CO CONC2019/0010975A patent/CO2019010975A2/es unknown
-
2020
- 2020-09-29 US US17/035,956 patent/US11591389B2/en active Active
-
2021
- 2021-10-27 AU AU2021257983A patent/AU2021257983B2/en active Active
-
2023
- 2023-02-03 JP JP2023015469A patent/JP2023055895A/ja active Pending
- 2023-02-07 US US18/165,614 patent/US20230242639A1/en not_active Abandoned
-
2025
- 2025-03-18 JP JP2025043151A patent/JP2025102812A/ja active Pending
- 2025-05-27 AU AU2025203947A patent/AU2025203947A1/en active Pending
- 2025-09-19 US US19/334,502 patent/US20260078180A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019010975A2 (es) | Anticuerpos anti-par2 y usos de los mismos | |
| CL2018003378A1 (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno. | |
| AR114002A1 (es) | Anticuerpos a lilrb2 | |
| NI202000086A (es) | Agentes vinculantes de psma y usos de los mismos | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| MX2018015853A (es) | Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137). | |
| MX2018005546A (es) | Anticuerpos que se unen especificamente a pd-1 y tim-3 y sus usos. | |
| MX391028B (es) | Anticuerpos que se unen a cd39 y sus usos | |
| MX2020013468A (es) | Anticuerpos il-11ra. | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| MX2019014577A (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso. | |
| CU24481B1 (es) | Moléculas de anticuerpo que se unen a lag-3 | |
| CO2018001624A2 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
| NI201800044A (es) | Anticuerpos agonísticos que se unen específicamente a cd40 humano y métodos de uso | |
| CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
| PE20171067A1 (es) | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas | |
| CO2018000710A2 (es) | Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador | |
| MX2018009228A (es) | Proteínas de unión a antigeno que se unen a pd-l1. | |
| MX2020001909A (es) | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas. | |
| MX2016009961A (es) | Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas. | |
| CR20150575A (es) | Anticuerpos humanos pac1 | |
| EA201892096A1 (ru) | Нейтрализующие моноклональные антитела к il-25 и их применение | |
| MX2019004371A (es) | Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos. | |
| MX389103B (es) | Anticuerpos contra ticagrelor y métodos de uso. | |
| CL2020000920A1 (es) | Anticuerpo monoclonal anti-il-5ra. |